Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia

Area of Science:

• Cardiology
• Hematology

Background:

• Severe thrombocytopenia presents a significant challenge for patients requiring antiplatelet therapy post-acute coronary syndrome (ACS).
• Myelodysplastic syndromes (MDS) are associated with dysfunctional platelets, increasing bleeding risk.
• Optimal management strategies for atherosclerotic cardiovascular disease in MDS patients remain unclear.

Observation:

• A case report details a patient with MDS-related thrombocytopenia who developed pericardial effusion and cardiac tamponade.
• The patient had undergone percutaneous transluminal coronary angioplasty with drug-eluting stent implantation for non-ST-segment elevation ACS ten weeks prior.
• This clinical scenario underscores the complexity of balancing antithrombotic needs with bleeding risks.

Findings:

• The case illustrates the difficulties in managing patients with both severe thrombocytopenia and acute coronary syndrome.
• Dysfunctional platelets in MDS exacerbate bleeding complications, complicating treatment decisions.
• There is a lack of robust data to guide treatment recommendations in such complex cases.

Implications:

• Individual case reports are valuable for informing clinical practice when evidence is limited.
• Further research is needed to establish evidence-based guidelines for managing cardiovascular disease in thrombocytopenic patients.
• This case emphasizes the need for multidisciplinary approaches involving cardiology and hematology.